



## The Atherosclerosis and Lipid Lowering- is there a Need for New Agents

Leonardo Roever<sup>1\*</sup>, Elmiro Santos Resende<sup>1</sup> and Giuseppe Biondi-Zoccai<sup>2,3</sup>

<sup>1</sup>Department of Clinical Research, Federal University of Uberlândia, Brazil

<sup>2</sup>Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

<sup>3</sup>Eleonora Lorillard Spencer Cenci Foundation, Rome, Italy

\*Corresponding author: Leonardo Roever, Department of Clinical Research, Av. Pará, 1720-Bairro Umuarama, Uberlândia-MG-CEP 38400-902, Brazil, Tel: 553488039878; E-mail: [leonardoroever@hotmail.com](mailto:leonardoroever@hotmail.com)

Received date: March 11, 2020; Accepted date: March 13, 2020; Published date: March 23, 2020

Copyright: © 2020 Roever L et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Editorial

Cardiovascular disease (CVD) is the leading cause of death worldwide. Among well-known risk factors, such as visceral obesity, sedentary lifestyle, metabolic syndrome, smoking, hypertension, age, gender, family history of heart attacks, diabetes, low levels HDL-C, high levels of LDL-C and total cholesterol are very strong predictors of CVD events and death [1-5].

In recent years, there have been significant advances in the elucidation of biomarkers of atherosclerotic disease, and also their pathogenesis, prevention and treatment. Atherosclerosis is a systemic inflammatory disease characterized by on-going progression in response to systemic risk factors and local pro-atherogenic stimuli that leads to acute myocardial infarction, stroke and lower limb ischemia [6].

An intriguing question is what is the real level cardio protective LDL cholesterol? Especially for patients with a history of heart attack, peripheral artery disease, or stroke: is 70 mg/dL, which is currently recommended or should go down to levels of 40 or 30 mg/dL?

Statins has substantially reduced CVD events around the world and is recommended as first-line therapy for CVD management. However, a need for other lipid-lowering agents, because some patients do not tolerate statins due to adverse events, or cannot reach LDL-C level desired because of high levels of LDL-C, or patients with very high risk cardiovascular events need more intensive reduction therapy [7-9]. Can we pay the benefits of these new agents when statins are effective and inexpensive?

Zhang et al. reported a meta-analysis study to evaluate the safety and efficacy of anti-PCSK9 antibodies in randomized, controlled trials (RCTs). Twenty-five RCTs encompassing 12,200 patients were included. The study showing largely no significant difference between anti-PCSK9 antibodies and placebo (or ezetimibe), except that alirocumab was associated with reduced rates of death (relative risk (RR): 0.43, 95 % CI: 0.19 to 0.96,  $P=0.04$ ) and an increased rate of injection-site reactions (RR: 1.48, 95 % CI: 1.05 to 2.09,  $P=0.02$ );

evolocumab reduced the rate of abnormal liver function (RR: 0.43, 95 % CI: 0.20 to 0.93,  $P=0.03$ ), both compared with placebo. Evolocumab and alirocumab substantially reduced the LDL-C level by over 50%, increased the HDL-C level, and resulted in favourable changes in other lipids [9].

New agents, as well as prevention programs should be implemented in order to decrease the morbidity and mortality caused by atherosclerotic events.

### References

1. Oliveira GBF, Avezum A, Roever L (2015) Cardiovascular disease burden: evolving knowledge of risk factors in myocardial infarction and stroke through population-based research and perspectives in global prevention. *Front Cardiovasc Med* 2: 32.
2. Roever L, Pinto IM, Chagas AC (2015) The association of left ventricular mass with coronary atherosclerosis and myocardial ischemia: cause and effect or simple association? *Eur Heart J Cardiovasc Imaging* 16: 156-157.
3. Roever L, Resende ES, Diniz AL, Penha-Silva N, Veloso FC, et. al. (2015) Ectopic adiposopathy and association with cardiovascular disease risk factors: The Uberlândia Heart Study. *Int J Cardiol* 190: 140-142.
4. Roever L, Veloso FC, Resende ES (2015) Visceral Fat, Atherosclerosis and Coronary Artery Disease. *Intern Med* 5: 188.
5. Roever L, Resende ES (2015) Coronary Microvascular Dysfunction. *International Journal of Cardiovascular Sciences* 28, 152-159.
6. Koskinas KC, Windecker S, Raber L (2015) Regression of coronary atherosclerosis: Current evidence and future perspectives. *Trends in Cardiovascular Medicine*.
7. Stone NJ, Robinson JG, Lichtenstein AH, Bairey MC, Blum CB, et al. (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 63: 2889-2934.
8. Dadu RT, Ballantyne CM (2014) Lipid lowering with PCSK9 inhibitors. *Nat Rev Cardiol* 11: 563-575.
9. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QA, et. al. (2015) Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Medicine* 13: 123.